Address

Abbott Laboratories
100 Abbott Park Road
Abbott Park, IL 60064
United States

Open map


Recent investment activity

KANDO id: 37787

Corporate information

Registration country

Official identities

US CIK 0000001800

Funding rounds

Actual initial investment stage
N/A (3)

Investment activity status
Active investor

Selected investments

Displaying 1 - 18 of 18
Profile Country Date Funding
Cardiac Concepts Inc Now known as Respicardia Inc Series C Initial investment
CFR Pharmaceuticals Acquisition Initial investment led the round (USD 2,900,000,000)
Evalve Acquisition Initial investment led the round USD 410,000,000 (USD 410,000,000)
Evalve Inc Acquisition Initial investment 410,000,000 (USD 410,000,000)
Facet Biotech Acquisition Initial investment USD 450,000,000 (USD 450,000,000)
Hydra Biosciences Inc N/A Initial investment
Ibis Biosciences Acquisition Initial investment led the round USD 215,000,000 (USD 215,000,000)
Icagen Inc Biopharmaceutical company developing small molecule therapeutics that target ion channels for treatment of a variety of diseases. N/A Initial investment
IDEV Technologies Inc Developer of next generation medical devices for use in the interventional radiology, vascular surgery, and cardiology device marketplace. Acquisition Initial investment led the round USD 310,000,000 (USD 310,000,000)
Integrated Vascular Systems Inc Medical device company developing devices to treat congestive heart failure. Acquisition Initial investment
OptiMedica Corp Acquisition Initial investment led the round USD 400,000,000 (USD 400,000,000)
Perclose Inc Acquisition Initial investment USD 680,000,000 (USD 680,000,000)
Solvay Pharmaceuticals Acquisition Initial investment led the round USD 6,600,000,000 (USD 6,600,000,000)
Spinal Concepts Inc Designer of spinal fixation technology for the medical industry (implants). Acquisition Initial investment 170,000,000 (USD 170,000,000)
Topera Inc Acquisition Initial investment led the round USD 250,000,000 (USD 250,000,000)
Triangle Pharmaceuticals Inc Anti-viral and oncology licensing company. N/A Initial investment
ViroPharma Inc Provider of life-saving medicines for life-threatening diseases. Acquisition Initial investment led the round USD 495,000,000 (USD 495,000,000)
Visiogen Inc A medical device company focused on dual-optic accommodating intraocular lens, called Synchrony, for the treatment of age-related vision loss. Acquisition Initial investment USD 400,000,000 (USD 400,000,000)

Team

Employee Position
Miles White
N/A
Responsibilities: Executive Officer

Past employees

Selected Products / Customers

Selected Suppliers

80141602 - Public relation services

United States

Financials